Chapter 5

Valuation and Buybacks

At $224.82 (July 16, 2026) Molina is a roughly $11.5 billion equity on about 51 million shares. That price is not cheap against anything the company earns today — 20x its 2025 adjusted result, 27x the 2027 consensus — and cheap only against management's 2029 target of $25 adjusted EPS, which it discounts at 9x. Trailing free cash flow is negative, so the reader's 8–10% FCF-yield bar is not met on the record; it is met only on a mid-cycle that has yet to appear in a cash-flow statement.

Sources: price per market data as reported; shares outstanding of 51 million and stockholders' equity from the FY2025 10-K balance sheet [1]; adjusted EPS of $11.03 from the Q4/FY2025 earnings release [2].

This chapter takes the durable-but-rebid top line (Revenue Durability) and the re-based margin (Margin Reset) as given, and asks what the current price pays for them, whether the cash returns are being spent well, and whether the 2024–2026 selloff cut the price by more than it cut the value.

What the price pays for

Molina has no single "right" earnings number right now, because 2026 is a guided trough and 2029 is a management target. The honest approach is to price the stock against each rung of that ladder and let the reader see the spread. On the near rungs it is expensive; on the far rung it is cheap; the entire gap is the recovery you are asked to underwrite.

Sources: 2026 guide of at least $5.00 adjusted EPS [3]; 2027 consensus per analyst estimates as reported; 2025 actual adjusted EPS [4]; 2029 target of $25 adjusted EPS [5]; normalized figure derived below.

The "normalized on today's revenue" rung is the one the reader most needs and the one no feed supplies, so it is built explicitly. Take 2025's premium and total revenue as the base, apply management's own re-based long-term adjusted pre-tax margin of 2–3% (midpoint 2.5%) rather than the 4–5% it targeted before 2025 [6], tax it at the recent ~24% rate, and divide by 51 million shares. That yields roughly $16.80 of adjusted EPS on today's book of business — about a $16–18 range across the 2–3% margin band — or about 13x. It is the multiple you pay if Molina neither shrinks nor grows and simply earns its stated normal margin. Everything below that P/E (toward the 9x on $25) requires the premium base to compound from about $43 billion toward the $64 billion the company targets for 2029 [7]; everything above it (toward the 20–44x on 2025–2026) is what you actually pay while the rate-versus-trend gap (Margin Reset) is still open.

The free-cash-flow screen it does not clear

For a reader whose first filter is a consistent 8–10% free-cash-flow yield, Molina fails the filter on the record, and the reason matters more than the fact. Reported operating cash flow was negative $535 million in 2025 and free cash flow negative $636 million; the Cash and Capital chapter traced that to the timing of government receivables and payables rather than to capital spending, which never exceeds about $101 million a year. But the reader's stated aversion is precisely to wavering cash flow, and Molina's has wavered from a $2.1 billion inflow (2021) to a $535 million outflow (2025).

Source: free cash flow (operating cash flow less capital expenditure) from FY2021–FY2025 cash-flow statements, as reported, divided by the current ~$11.5 billion market capitalization; illustrative, since each year's cash was earned on a different share count and market value. [8]

Measured against today's market value, Molina's own cash generation has swung from an 18% yield to a negative one inside five years. The reader's 8–10% bar is cleared comfortably in the strong years and missed entirely in 2025. A cross-cycle proxy is kinder but still not decisive: on the normalized ~$16.80 of earnings derived above — and with capex trivial and mid-cycle cash conversion running near one times net income over 2020–2025 (Cash and Capital) — a mid-cycle free-cash-flow yield lands around 7–8%, at the low edge of the reader's range rather than through it. The honest statement is that Molina meets the FCF-yield screen only on a normalized basis it has not yet demonstrated, and its cash flow has the volatility the reader explicitly dislikes.

No asset floor beneath the price

Tangible book value is thin, so the reader looking for a balance-sheet backstop will not find one here. Stockholders' equity of $4,069 million carries $1,958 million of goodwill and $237 million of other intangibles, leaving about $1,874 million of tangible equity, or roughly $36.75 per share [9]. At $224.82 the stock trades at about 6.1x tangible book.

Source: FY2025 10-K — stockholders' equity from the Consolidated Balance Sheets [10]; goodwill of $1,958M and intangibles of $237M per the impairment risk factor [11].

A 6x multiple of tangible book is not, by itself, a warning: Molina is a capital-light services business that earned a 26% return on equity as recently as 2024, and such a business should trade well above the accounting value of its net assets. But it means the price rests entirely on the earnings stream and the state contracts behind it, not on any liquidation value. For context, the tangible equity is smaller than the roughly $3.1 billion of statutory minimum capital locked inside the regulated subsidiaries (Cash and Capital) — the tangible net worth attributable to shareholders is modest relative to the balance sheet the business runs on.

The same caution applies to the EV/EBITDA lens the reader uses as an alternative gate. On the parent-net-debt framing that the cash chapter established as the honest one — about $3.5 billion of net debt at the entity that owns the equity — enterprise value is roughly $15 billion.

Source: EBITDA derived as operating income plus depreciation and amortization from the FY2024–FY2025 filings; enterprise value of ~$15.2B = ~$11.5B market cap plus ~$3.5B parent-level net debt (per Cash and Capital) plus finance leases. [12]

On depressed 2025 EBITDA the stock is about 15.6x — above the reader's sub-12 gate; on pre-break 2024 EBITDA it is about 8x — through it. As with the P/E ladder, the multiple clears the bar only if profitability normalizes. (EV/EBITDA is in any case an awkward lens for a health plan, where regulated cash sits against reserves and the industry prices itself on adjusted EPS and the medical care ratio; the consolidated net-cash framing would flatter these numbers to 3–7x, which is why the parent-net-debt view is the one that should govern.)

Buybacks: real, large, and imperfectly timed

The reader treats buybacks as a test of whether management exploits a depressed price. Molina passes on scale and fails on timing. It has no dividend, and it returned $1.0 billion in each of 2024 and 2025 entirely through repurchases, taking the diluted share count from about 58 million, where it had sat for years, down toward 51 million.

Source: weighted diluted share counts from FY2019–FY2025 income statements and the Q1 2026 10-Q, as reported. [13]

The timing, however, is a genuine mark against management's capital discipline, and it is worth stating precisely rather than glossing. Of the $1.0 billion spent in 2025, half went out in the first quarter — about 1,679,000 shares at an average cost of $297.83 — exhausting the October 2024 authorization just before the stock collapsed. The second $500 million was spent in the third quarter at an average of $175.50, into the weakness [14]. The shares bought at $298 were underwater within months, as the stock reached $122.65 in February 2026.

Sources: Q1 2025 repurchase of ~1.68M shares at $297.83 and Q3 2025 repurchase of ~2.85M shares at $175.50 per Note 13 [15]; low and current prices per market data as reported.

So the record is mixed rather than exemplary: management did shrink the count by roughly a tenth in eighteen months, but it spent its first tranche near the peak and only its second into the fear. Two constraints bear on what comes next. About $500 million remained under the April 2025 authorization as of February 10, 2026, running through the end of 2026 [16]. But the parent holds only about $205 million of cash [17], so further repurchases depend on the ~$1 billion a year the subsidiaries can upstream — the same dividend capacity the cash chapter identified. At today's price, completing the remaining $500 million would retire only about another 2 million shares.

The selloff and the value behind it

The reader hunts for names where a fear-driven selloff takes more off the market cap than off the net present value of the cash flows. Molina fits the shape of that setup; whether it fits the substance is the question the earlier chapters leave open.

The market-cap move is not in doubt. From a March 2024 peak near $419 on about 58 million shares — roughly $24 billion — the equity fell to about $6.3 billion at the February 2026 low, an ~$18 billion, ~74% drawdown, before recovering to about $11.5 billion. Against that, management's stated earnings target barely moved: the 2029 adjusted EPS goal is $25 [18], essentially the $22.65 the company earned in 2024. If that target is credible, the value fell far less than the price, and the recovery still has room — the bull's core claim.

The bear's answer is the substance the price move may be right about. The Margin Reset chapter found the profitability re-basing to be largely structural: management itself cut its long-term pre-tax margin target from 4–5% to 2–3% and lifted its medical-care-ratio target by roughly 350 basis points. A business earning half its former margin per premium dollar, whose revenue is competitively rebid rather than owned (Revenue Durability), and whose cash flow wavers, deserves a lower multiple than it once carried — so part of the $18 billion is a re-rating that should not reverse, not an overshoot that should. And the $25 target is not this year's earnings; it needs the premium base to compound about 15% a year to $64 billion while the margin holds, which the same chapters show is exposed to policy and rate-setting the company does not control.

At $224.82 the stock sits between these readings, not at either. It is roughly 13x a normalized result on today's revenue and 9x the 2029 target — pricing neither a permanent impairment (which 13x on flat earnings would not be) nor the full realization of $25 (which would leave far more than 9x on the table). What would move the read is checkable and dated: 2026–2027 Medicaid rate updates that narrow the rate-versus-trend gap would validate the recovery rungs of the ladder; another year of negative or soft operating cash flow, or a lost Washington reprocurement, would push the fair multiple back toward the normalized-today floor and leave the reader's FCF-yield screen unmet.